Eur J Endocrinol
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Erratum for Lund et al., Eur J Endocrinol 158 (1) 35-46.
DOI: 10.1530/EJE-07-0500e
European Journal of Endocrinology, Vol 158, Issue 3, 443-445
Copyright © 2008 by European Society of Endocrinology
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Lund, S. S
Right arrow Articles by Vaag, A. A
Right arrow Search for Related Content
PubMed
Right arrow Articles by Lund, S. S
Right arrow Articles by Vaag, A. A

ERRATUM

Impact of metformin versus the prandial insulin secretagogue, repaglinide, on fasting and postprandial glucose and lipid responses in non-obese patients with type 2 diabetes

Søren S Lund1, Lise Tarnow1, Merete Frandsen1, Ulla M Smidt1, Oluf Pedersen1,2, Hans-Henrik Parving2,3 and Allan A Vaag1,4

1 Steno Diabetes Center, Niels Steensens Vej 2, 2820 Gentofte, Denmark2 Faculty of Health Sciences, University of Aarhus, Aarhus, Denmark3 Department of Medical Endocrinology, Rigshospitalet, University of Copenhagen, 2100 Copenhagen, Denmark and 4 Department of Endocrinology, University of Lund, S-20502 Malmo, Sweden

(Correspondence should be addressed to S S Lund; Email: sqrl{at}steno.dk)

The authors and the journal apologise for errors in the above paper which appeared in 158 (1) 35–46. In this paper, on page 38, under the results section, the first sentence of the second paragraph should read as follows:

‘At enrolment, 29 (30%) patients received lipid-lowering treatment as concomitant non-study medication (statin therapy, n=22 (23%) – hereof 20 patients (21%) during the entire study period; fish oil, n=8 (8%); acipimox, n=1 (1%); none of the patients received fibrates).’

On page 40, in the results section under the heading ‘Subgroups of patients according to ongoing statin treatment, pre-study antihyperglycaemic treatment regimens or known macrovascular disease’ the first sentence should read as follows:

‘Without fasting adjustment: statin treatment (n=18): –0.39 mmol/l (–0.62; –0.17), P=0.001; no statin treatment (n=55): –0.16 mmol/l (–0.29; –0.02), P=0.021; fasting adjusted: statin treatment (n=18): –0.25 mmol/l (–0.38; –0.12), P<0.001; no statin treatment (n=54): –0.08 mmol/l (–0.15; –0.00), P=0.041).’

On page 39 and on page 41, Tables 2 and 3 should appear as follows:


View this table:
[in this window]
[in a new window]

 
Table 2 Comparison of effects of metformin and repaglinide on fasting and postprandial glycaemic variables during a standardized fatty meal test in non-obese patients with type 2 diabetes.

 

View this table:
[in this window]
[in a new window]

 
Table 3 Comparison of effects of metformin and repaglinide on fasting and postprandial lipid variables during a standardized fatty meal test in non-obese patients with type 2 diabetes.

 





This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Lund, S. S
Right arrow Articles by Vaag, A. A
Right arrow Search for Related Content
PubMed
Right arrow Articles by Lund, S. S
Right arrow Articles by Vaag, A. A


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS